The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Open accessPublished version of a preprint
Abstract
Interleukin-11 is important for lung fibroblast activation in idiopathic pulmonary fibrosis, and its signaling represents a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IL-11 is a key driver of myofibroblast activation and differentiation in IPF41”
From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [41]
In the citing paper
“Microbiota driven intestinal fibrosis may be mediated by induction of the IL-33 receptor ST2 on epithelial cells157 or the pro-fibrotic action of tumor necrosis factor-like cytokine 1A (TL1A)158”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Bootstrap Methods and their Application
Davison, A. C., & Hinkley, D. V. (1997) · doi:10.1017/cbo9780511802843 · Cited by 7,350
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 2×
“Antifibrotic small-molecule drugs such as nintedanib (5) and pirfenidone (6) are approved for the treatment of IPF but have notable toxicities (2).”
BackgroundMethodSelf-citationMapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt
Durinck, S., Spellman, P. T., Birney, E., & Huber, W. K. (2009) · Nature Protocols · doi:10.1038/nprot.2009.97 · Cited by 4,156
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–311 of 311
Wang, L., Zhu, L., Peng, S., Zheng, Q., Zhang, Q., Chen, Y., Lu, Y., & Deng, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1764404
Wang, M., Qian, Y., Huang, E., Chu, C., Gao, T., Chen, S., Zhao, N., Luo, C., Liu, Y., Zheng, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1911726
Yang, Y., Zhang, H., Du, J., Sun, W. C., Peng, X., & Fan, J. (2026) · Advanced Materials · doi:10.1002/adma.74615
Pohl, P. C., Zapotoski, L. N. K., Sardinha, L. R., Villas-Boas, I. M., Pidde, G., & Tambourgi, D. V. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1880784
Development of a Lactam-Bridged Peptide as Interleukin-11 Antagonist for Renal Fibrosis Treatment
Yang, X., Zhao, N., Zheng, R., Li, J., Wu, Y., Ma, Z., Pang, N., Meng, X., Liu, R., Xiong, X., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00034
Chen, H., & Liang, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1951110
Koroknai, V., Szász, I., Hamdan, M., Berecz, Á., & Balázs, M. (2026) · Biomolecules · doi:10.3390/biom16101510
Yu, Z., Dong, X., Li, F., Zhang, Y., Dai, S., Cao, N., Jia, X., Zhao, J., Wang, B., Chang, W., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.10.024
Design of full-length agonist and antagonist antibodies for hard targetsPreprint
Aglietti, R. A., Ansari, R., Bowers, P. M., Buelles, T.-H., Chauvin, H., Duplay, T. M., Hibouri, M. E., Jorda, J., Laniado, J., Malago, M. M. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.21.760573
Rethinking inflammaging: Spatiotemporal decoupling and the failure of inflammatory regulation
Deng, X., Wang, L., Luo, M., & Wu, J. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103438
Ren, J., 曹东阳, Zhang, K., Liu, P., Wu, Q., Zhu, J., Fan, C., Zhang, H., Zhang, L., & Guo, C. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.183969
Metadata
- Authors
- Ng, B., Dong, J., D’Agostino, G., Viswanathan, S., Widjaja, A. A., Lim, W.-W., Ko, N. S. J., Tan, J., Chothani, S. P., Huang, B., Xie, C., Pua, C. J., Chacko, A.-M., Guimarães-Camboa, N., Evans, S. M., Byrne, A. J., Maher, T. M., Liang, J., Jiang, D., Noble, P. W., Schafer, S., & Cook, S. A.
- Affiliations
- National University of Singapore (SG)
- National Heart Centre Singapore (SG)
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt 60590, Germany.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA.
- Imperial College London (GB)
- Royal Brompton Hospital (GB)
- Cedars-Sinai Medical Center (US)
- National Heart Centre Singapore, 169609 Singapore, Singapore.
- Corresponding author
- Ng, Benjamin
- Dong, Jinrui
- D’Agostino, Giuseppe
- Cook, Stuart A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-09-25
- Volume
- 11
- Issue
- 511
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2975410560
- Semantic Scholar
- 707edf16b55c02f433b992ddc906064a1c8f30f7
- Cited by
- 314
- References
- 92
- Citations by year
- 2026: 41 · 2025: 42 · 2024: 51 · 2023: 45 · 2022: 45 · 2021: 55 · 2020: 29 · 2019: 6
- FWCI
- 24.67
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nd
- Locations
- Science Translational Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
- PubMed (publishedVersion)
- Funders
- National Medical Research Council (NMRC) Singapore (NMRC/OFYIRG/0053/2017)
- NIHR Clinician Scientist Fellowship (HIHR Ref: CS-2013-13-017)
- British Lung Foundation Chair in Respiratory Research (C17-3)
- the National Medical Research Council (NMRC) Singapore STaR awards (NMRC/STaR/0011/2012)
- National Medical Research Council (NMRC) Singapore STaR awards (NMRC/STaR/0029/2017)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- interleukin-11, idiopathic pulmonary fibrosis, pulmonary fibrosis, lung fibroblast activation, myofibroblast activation, bleomycin-induced fibrosis, ERK signaling, Smad signaling, lung inflammation, therapeutic target
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Severity of Illness Index, Signal Transduction, Up-Regulation, Interleukin-11, Mice, Knockout, Interleukin-11 Receptor alpha Subunit, Idiopathic Pulmonary Fibrosis, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
